Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03102632
Other study ID # 1701017921
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 1, 2017
Est. completion date December 31, 2021

Study information

Verified date October 2023
Source The Rogosin Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients affected by Autosomal Dominant Polycystic Kidney Disease (ADPKD) need a safe and effective long-term treatment regimen. Unfortunately, there are still no disease-specific treatment for ADPKD approved in the US. A rational step towards identifying such agents is to test therapies that have a proven safety profile with mechanisms of action that can counter the disease progression. The purpose of this study is to investigate whether drinking increased amounts of water (water loading) might slow down polycystic kidney growth or kidney function decline. Water loading can cause the suppression of a pathway that causes fluid buildup and cyst growth. High water intake has been safely used in the clinical setting, such as in the case of kidney stone therapy. New York State tap water is widely available and safe, making it highly cost-effective as well.


Description:

The study will involve 11 visits to the study site over 19 months. Participants will need to follow specific dietary and fluid recommendations. There will be physical examinations and medical history assessments at each visit. Testing will include undergoing magnetic resonance imaging (MRI), blood and urine tests. Study participants will be compensated for their time. Detailed study procedures will be reviewed upon contact with the study team.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - pre-existing diagnosis of Autosomal Dominant Polycystic Kidney Disease - estimated glomerular filtration rate of 40 ml/min or greater - urine osmolality > 400 mOsm/L Exclusion Criteria: - estimated glomerular filtration rate less than 40 ml/min - low blood sodium levels - syndrome of inappropriate diuretic hormone - use of thiazide diuretics or selective serotonin reuptake inhibitors (SSRIs) - use of tolvaptan, another vasopressin receptor antagonist, vasopressin agonists or dDAVP - contraindications to magnetic resonance imaging (MRI) (pacemakers, defibrillators, implanted electronic devices, metallic foreign body)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High Water Intake
After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.

Locations

Country Name City State
United States The Rogosin Institute New York New York

Sponsors (2)

Lead Sponsor Collaborator
The Rogosin Institute Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in total kidney volume, as measured from magnetic resonance imaging Total kidney volumes will be measured before and after the period of high water intake. Kidney volume growth with high water intake will be compared to baseline kidney volume growth. 18 months
Secondary Kidney function change Blood creatinine levels will be measured and compared before and after the high water intake period. 18 months
Secondary Change in urine and blood markers of response to high water intake Blood and urine biomarkers of response to high water intake will be measured before and after the period of high water intake. 18 months.
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Recruiting NCT03596957 - Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Phase 4
Terminated NCT04064346 - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT03203642 - Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Phase 2
Recruiting NCT05500157 - Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts N/A
Recruiting NCT04111692 - A Prospective Observational Study of Foam Sclerotherapy .
Recruiting NCT04907799 - Daily Caloric Restriction in ADPKD N/A
Completed NCT05401409 - Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease N/A
Terminated NCT03918447 - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Phase 3
Terminated NCT03749447 - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Phase 3
Recruiting NCT05228574 - Treatment of Vascular Stiffness in ADPKD Phase 4
Completed NCT04908462 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers Phase 1
Completed NCT03858439 - Dietary Intervention in ADPKD on Tolvaptan N/A
Recruiting NCT06391450 - Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) Phase 4
Recruiting NCT05478083 - A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Phase 2
Recruiting NCT05996731 - Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases N/A
Recruiting NCT06193616 - Outcome of ADPKD With Octreotide LAR
Completed NCT05646420 - Thyroid Hormones in ADPKD N/A
Completed NCT03366337 - A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Phase 2
Active, not recruiting NCT03273413 - Statin Therapy in Patients With Early Stage ADPKD Phase 4